The 20th century saw great strides in curing childhood cancer, thanks primarily to the discovery that broadly toxic chemotherapy agents could kill malignant cells. Once virtually incurable, pediatric cancer now has an overall long-term survival rate topping 80 percent.
In the 21st century, attention is turning to additional, less toxic developments in cancer therapy. Lisa Diller, MD, Chief Medical Officer of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, cites four coming changes:
- Precision medicine treatments targeting specific genetic and epigenetic pathways
- Immunotherapy drugs gaining FDA approval
- Innovations to reduce treatment toxicity
- A stronger focus on improving survival of childhood cancer globally.